TF and blood coagulation disease: Rapamycin has been previously shown to enhance tissue factor (TF) activity, leading to an increased risk of thromboembolic events [52,53]; however, studies have also shown that rapamycin treatment helps mitigate coagulopathies via D-dimer reduction [54,55].